SALEM – Jim Calandra, president and CEO of Gamma Medica and the Gamma Medica team welcomed U.S. Sen. Kelly Ayotte, R-N.H., Friday for a company tour and technology review.
Specializing in advanced digital molecular imaging technology, Gamma Medica’s product, the LumaGEM Molecular Breast Imaging system clearly highlights tumors obscured by dense breast tissue, enabling the early detection of breast cancer.
Approximately 40 percent of women have dense breast tissue, which makes presently available mammography screening unlikely to identify early-stage cancers.
“Gamma Medica provides a leading-edge technology designed to aid breast radiologists in diagnosing difficult cases, particularly in women with dense breast tissue,” Calandra said. “We were pleased to have Sen. Ayotte learn more about the advancement of medical technology that enables women with dense breast tissue to have timely and accurate information concerning their health.”
Gamma Medica recently moved to New Hampshire and has 26 employees.